Kyverna Therapeutics (KYTX) Financials

Kyverna Therapeutics (NASDAQ: KYTX) remains in a pre-revenue, clinical-stage position, and the latest quarter shows a company still burning significant cash while relying on its investment portfolio to fund operations. The balance sheet remains substantial, but the cash runway is clearly being consumed by ongoing R&D spending and operating losses.

• Kyverna ended Q1 2026 with $32.2 million in cash and $204.3 million in short-term investments, giving it $236.4 million in liquid resources.
• The company still has a strong equity base of $195.6 million, which provides some financial cushion despite ongoing losses.
• Interest and investment income was meaningful in Q1 2026 at $2.33 million, helping offset some of the operating burn.
• Selling, general and administrative expense fell to $11.3 million from $9.3 million in Q4 2025 and was lower than the prior year’s recent peaks in some periods, suggesting some expense discipline outside of R&D.
• The company’s quarterly net cash outflow from financing activities was minimal in Q1 2026, indicating it was not heavily dependent on immediate new financing during the quarter.
• Revenue remained $0 across all periods shown, so Kyverna is still entirely dependent on capital markets and its balance sheet to fund development.
• R&D spending stayed high at $30.1 million in Q1 2026, which is typical for a biotech company advancing clinical programs but also keeps losses elevated.
• The company’s balance sheet includes $24.8 million of long-term debt, which is manageable relative to assets, but still adds leverage to a cash-burning business.
• Operating cash outflow in Q1 2026 was $41.6 million, and this is the key number investors should watch when evaluating runway.
• Kyverna reported a net loss of $39.7 million in Q1 2026, or $0.66 per share, underscoring that the business is still far from profitability.
• Cash and equivalents declined sharply from $34.2 million in Q3 2025 to $32.2 million in Q1 2026, while the broader liquid balance also fell from recent highs as investments were used to fund losses.
• Quarterly cash burn remains significant: net change in cash was -$91.9 million in Q1 2026, driven primarily by operating losses and investment activity.
• Compared with Q1 2025, total current assets fell from $247.7 million to $241.7 million, and total assets declined from $261.0 million to $257.0 million, showing a gradual erosion in the asset base.
• The company’s quarterly losses remain persistent, with Q1 2026 loss slightly worse than Q4 2025 ($37.8 million) and similar to the other recent quarters, indicating no clear trend toward breakeven.

Over the last four years, Kyverna’s pattern is consistent: no revenue, heavy R&D spending, recurring quarterly losses, and reliance on cash/investment balances to finance operations. The major positive is that the company still has a meaningful liquid balance and equity base. The major risk is that the burn rate remains very high, so future financing needs are likely unless clinical progress changes the story.